CN105996059A - Composition for increasing bone mineral density - Google Patents
Composition for increasing bone mineral density Download PDFInfo
- Publication number
- CN105996059A CN105996059A CN201610428074.4A CN201610428074A CN105996059A CN 105996059 A CN105996059 A CN 105996059A CN 201610428074 A CN201610428074 A CN 201610428074A CN 105996059 A CN105996059 A CN 105996059A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- compositions
- bone density
- increasing bone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 230000001965 increasing effect Effects 0.000 title claims abstract description 30
- 210000000988 bone and bone Anatomy 0.000 title abstract description 20
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract description 6
- 239000011707 mineral Substances 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 37
- 102000008186 Collagen Human genes 0.000 claims abstract description 24
- 108010035532 Collagen Proteins 0.000 claims abstract description 24
- 229940036811 bone meal Drugs 0.000 claims abstract description 17
- 239000002374 bone meal Substances 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000011777 magnesium Substances 0.000 claims abstract description 16
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 16
- 229920001202 Inulin Polymers 0.000 claims abstract description 14
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 14
- 229940029339 inulin Drugs 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 13
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 12
- 210000003022 colostrum Anatomy 0.000 claims abstract 2
- 235000021277 colostrum Nutrition 0.000 claims abstract 2
- 230000037182 bone density Effects 0.000 claims description 37
- 235000020243 first infant milk formula Nutrition 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 241000229143 Hippophae Species 0.000 claims description 8
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 8
- 244000299461 Theobroma cacao Species 0.000 claims description 8
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 8
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 235000020183 skimmed milk Nutrition 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 7
- 229920002774 Maltodextrin Polymers 0.000 claims description 7
- 229940035034 maltodextrin Drugs 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims 4
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 30
- 229960005069 calcium Drugs 0.000 description 30
- 239000011575 calcium Substances 0.000 description 30
- 229910052791 calcium Inorganic materials 0.000 description 30
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- 239000011574 phosphorus Substances 0.000 description 9
- 229910052698 phosphorus Inorganic materials 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 229960002737 fructose Drugs 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000008167 Magnesium Deficiency Diseases 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000004764 magnesium deficiency Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- DZBOBVOJNKUASM-UOXYZBCYSA-N (2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid;(2s)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.O[C@H]1CN[C@H](C(O)=O)C1 DZBOBVOJNKUASM-UOXYZBCYSA-N 0.000 description 1
- DDRAYWXTTWQAEA-HJXLNUONSA-N 2-aminoacetic acid;(2s,4r)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound NCC(O)=O.O[C@H]1CN[C@H](C(O)=O)C1 DDRAYWXTTWQAEA-HJXLNUONSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YMKIRWHSXOBLCF-UHFFFAOYSA-N [Mg].[P].[Ca] Chemical compound [Mg].[P].[Ca] YMKIRWHSXOBLCF-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- CADZRPOVAQTAME-UHFFFAOYSA-L calcium;hydroxy phosphate Chemical compound [Ca+2].OOP([O-])([O-])=O CADZRPOVAQTAME-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000006503 pathological mineralization Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001694 thigh bone Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000011121 vaginal smear Methods 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides a composition for increasing the bone mineral density. The composition is prepared by mixing, by weight, 1-50 parts of enzymatic bone meal, 1-20 parts of collagen peptides, 1-50 parts of inulin, 0.1-10 parts of magnesium, 0.1-10 parts of colostrum basic protein and 0.01-10 parts of yeast powder. Accordingly, all the components in the composition achieve the synergist effect, and the composition is significant in bone mineral density increasing effect, good in mouthfeel, easy to absorb and convenient to take.
Description
Technical field
The present invention relates to field of health care food, a kind of compositions for increasing bone density.
Background technology
Bone density, is an important symbol of bone mass, reflects osteoporosis degree, it was predicted that risk of fractures
The important evidence of property.Present stage improves bone density and generally requires supplementary calcium preparation, and existing calcium supplementing product master
Calcium gluconate to be had, calcium chloride and calcium lactate etc., owing to skeleton is to be made up of bone matrix and bone mineral
Complicated organism.The main component of bone matrix is collagen, and the main component of bone mineral is di
Calcium.First the generation of skeleton is synthesis collagen, and collagen fiber are intertwined to form substrate net, then calcium,
Phosphorus is deposited in collagen stroma net with the form of calcium hydroxy phosphate, does not therefore have the ossein cannot in skeleton
Cheng Qiwei skeleton, and the most many hydroxyapatite molecules and the accumulation of granule, do not have enough in skeleton
With carry out the ossein of eubolism, will be the strongest and unsound.Therefore, seek one to have
The health food of the increase bone density of effect has very important using value.
Summary of the invention
The technical problem to be solved is to provide a kind of compositions for increasing bone density.
For solving above-mentioned technical problem, the technical scheme is that
A kind of compositions for increasing bone density, by enzymolysis bone meal, collagen peptide, inulin, magnesium,
Just milk basic protein and yeast powder composition, enzymolysis bone meal 1-50 part, collagen peptide based on its parts by weight
1-20 part, inulin 1-50 part, magnesium 0.1-10 part, first milk basic protein 0.1-10 part, yeast powder 0.01-10
Part.
Preferably, the above-mentioned compositions for increasing bone density, enzymolysis bone meal 5-45 based on its parts by weight
Part, collagen peptide 2-15 part, inulin 3-40 part, magnesium 0.1-5 part, first milk basic protein 0.1-5
Part, yeast powder 0.01-5 part.
Preferably, the above-mentioned compositions for increasing bone density, enzymolysis bone meal 10-30 based on its parts by weight
Part, collagen peptide 2-10 part, inulin 5-30 part, magnesium 0.1-3 part, first milk basic protein 0.1-3
Part, yeast powder 0.01-4 part.
Preferably, the above-mentioned compositions for increasing bone density, enzymolysis bone meal 25 parts based on its parts by weight,
Collagen peptide 7 parts, inulin 18 parts, 2 parts of magnesium, first milk basic protein 2 parts, yeast powder 1.5 parts.
Preferably, the above-mentioned compositions for increasing bone density, also include the auxiliary of following parts by weight proportioning
Material: cocoa powder 1-40 part, skimmed milk powder 1-40 part, seabuckthorn fruit powder 1-20 part, maltodextrin 1-40
Part, fructose 0.1-30 part.
Preferably, the above-mentioned compositions for increasing bone density, also include the auxiliary of following parts by weight proportioning
Material: cocoa powder 5-30 part, skimmed milk powder 5-30 part, seabuckthorn fruit powder 2-15 part, maltodextrin 2-20
Part, fructose 0.1-20 part.
Preferably, the above-mentioned compositions for increasing bone density, also include the auxiliary of following parts by weight proportioning
Material: cocoa powder 5-20 part, skimmed milk powder 5-30 part, seabuckthorn fruit powder 2-10 part, maltodextrin 5-20
Part, fructose 1-15 part.
Preferably, the above-mentioned compositions for increasing bone density, also include the auxiliary of following parts by weight proportioning
Material: cocoa powder 13 parts, skimmed milk powder 15 parts, seabuckthorn fruit powder 8 parts, maltodextrin 6 parts, crystallization fruit
Sugar 5 parts.
The preparation method of the above-mentioned compositions for increasing bone density, specifically comprises the following steps that
(1) each component in prescription is weighed by prescription amount standby；
(2) by each component mix homogeneously, to obtain final product.
The usage and dosage of the above-mentioned compositions for increasing bone density: every day 1 time, each 10g, warm water
Punching food, can eat with other food simultaneously.
The invention has the beneficial effects as follows:
The above-mentioned compositions for increasing bone density, each component synergism, increase bone density effect notable,
And in good taste, easily absorb, it is simple to take (solid beverage dosage form)；Its preparation method is simple, is suitable for scale
The needs that chemical industry produces.
Detailed description of the invention
Below in conjunction with specific embodiment, technical scheme of the present invention is further described.
Embodiment 1
A kind of compositions for increasing bone density, by enzymolysis bone meal (Tian Shi group product), collagen protein
Peptide, inulin, magnesium, first milk basic protein and yeast powder composition, each amounts of components is shown in Table 1, each component is mixed
Close uniformly and get final product.
Table 1
The above-mentioned compositions for increasing bone density, in each component:
Enzymolysis bone meal (Tian Shi group product), animal bone rich calcium, and with people's bone photo seemingly, human body
Bone cells has stronger affinity to homologue's cell, thus utilization rate is high；Enzymolysis bone meal be with
Pure natural cattle vertebrae is raw material, processes through high-tech biological enzymolysis technology, is natural safe excellent
Matter calcium source；Enzymolysis bone meal is rich in the mineral of multiple needed by human, in addition to containing abundant calcium, phosphorus,
Possibly together with magnesium, ferrum, zinc, copper, violent etc., it it is nutrient complex；Calcium phosphorus ration science in enzymolysis bone meal
Rationally, the beneficially human body absorption to calcium；Enzymolysis bone meal is rich in several amino acids, collagen polypeptide and collagen egg
In vain, may advantageously facilitate the absorption of calcium；And through experimental results demonstrate, collagen protein plays the composition of effect and is
Functional dipeptides (hydroxyproline-proline, hydroxyproline-glycine) containing hydroxyproline, through people
Body can produce more functional dipeptides after absorbing.
Collagen peptide, the calcium in blood plasma is still transported bone by hydroxyproline contained in collagen protein
The vehicle of cell, if lacking collagen protein, prevents and treats merely osteoporosis with replenishing the calcium, more
Calcium also cannot improve, the amino such as glycine that collagen protein needs rich in human body, proline, hydroxyproline
Acid.Collagen protein is most important ingredient in extracellular matrix.
Inulin, water soluble dietary fiber, it is possible to the fiber type being dissolved in the water, there is stickiness, can be
Intestinal absorbs moisture in a large number, makes feces keep soft condition；Water-soluble fibre can effectively make in intestinal
Benefit mattress activation, promotes benefit bacterium amount reproduction, and the healthy ecology scientific research creating intestinal confirms, prebiotic
Bacterium, at the amount reproduction of intestinal, can treat the pseudomembranous enteritis caused because of a large amount of use antibiotic；Control
Treat constipation and chronic diarrhea；The liver protecting；Prevent and treat hypertension and arteriosclerosis and defying age, reduction blood
Clearing gallbladder sterin, prophylaxis of cancer, the absorption of promotion calcium phosphorus magnesium and the effect of suppression tumor growth；When inulin and
When calcium is taken in simultaneously, it does not only interfere with the body absorption to calcium, can play facilitation on the contrary.
Magnesium, experiment in vitro proves that magnesium can promote osteoblastic propagation and adhesion, promotes osteoblastic
Osteogenic activity；There is experiment to prove the disorder that magnesium deficiency can cause internal calcium ion to balance simultaneously, cause simultaneously
Parathyroid hormone and 1, the secretion of 25 (OH) 2-vitamin D reduces, and causes bone to reduce pathological mineralization；
Magnesium deficiency is easily caused osteoporosis, suitably supplements magnesium and can strengthen bone density, improves osseous tissue form, slow
Solve the symptoms such as osteoporosis.
Just milk basic protein, is approved for new resource food in 2009, has following features and function: live
Property albumen, molecular weight is little, can be done directly on bone cells, promotes skeleton metabolism, can coordinate into
Osteocyte and the activity of osteoclast, keep both dynamic equilibrium, promotes bone growth.
Yeast powder, can maintain stablizing of Serum Calcium Phosphorus concentration rich in VD, VD, when blood calcium concentration is low, and induction
Parathyroid hormone is secreted, and is discharged to kidney and osteocyte；In kidney pth except stimulate 1 carboxylase with
Suppressing outside 24 carboxylated enzymes, also promote phosphorus to discharge from urine, calcium is re-absorption in renal tubules；In bone
Pth and 1,25-(OH) 2-VD3 synergism, mobilizes out from bone by calcium；In small intestinal 1,25-
(OH) 2-VD3 promotes the absorption of calcium；Make blood calcium return to normal level from these three approach, feed back again control
The secretion of pth processed and 1, the synthesis of 25-(OH) 2-VD3；Thyroid C Cells is stimulated when blood calcium height,
Produce calcitonin, stop calcium to mobilize out from bone, and promote calcium and phosphorus to discharge from urine；Intestinal absorption
Phosphorus is active absorption, it would be desirable to be able to, sodium, glucose, 1, (8mg% when 25-(OH) 2-VD3 and serum paraoxonase are low
Below), stimulating 1, the synthesis of 25-(OH) 2-VD3, promotion small intestinal is to calcium, the absorption of phosphorus；Due to
Pth does not participate in reaction, thus calcium is discharged from urine and phosphorus is not discharged, so that blood calcium slightly rises, and phosphorus
Rise more, make serium inorganic phosphorus recover normal.
Above-mentioned each component influences each other, synergism, increases bone density effect notable.
Efficacy experiments is as follows:
One, bone density experiment is increased
(1) ovary excision: rat with dosage lumbar injection 1% Nembutal sodium solution of 30mg/kg bw,
Carrying out Bilateral oophorectomy after anesthesia, postoperative muscle injects the penicillin of 20,000 units, for three days on end.False
Operation group only excises 0.5g fat after opening abdominal cavity, retain bilateral ovaries.Rat ovary excises latter 5 days,
Carry out vaginal smear examination, reject ovary and excise incomplete rat.
(2) animal packet: above-mentioned female castrated rats is randomly divided into model control group, high dose by body weight
Calcium carbonate control group and sample basic, normal, high three dosage groups, respectively 0.9g/kg, 1.8g/kg, 5.4g/kg.Set simultaneously
Vertical sham operated rats.Often group 10, single cage is raised, and feeds 3 months.
(3) thighbone density measures: at the end of experiment, and rat is put to death in the dislocation of strength vertebra, peels off right femur, warp
105 DEG C are toasted 8 hours, after being cooled to room temperature, measure femur midpoint and the bone density (BMD) of distal end.
(4) calcium content of bone measures: after weighing the gross weight of femur, put into through HCl treatment dry cleansing
In triangular flask, add nitric acid+perchloric acid (4:1) mixed acid 15ml, after digestion, use deionized water constant volume,
Measure calcium content of bone with atomic absorption spectrophotometer, measure with State Bureau of Technical Supervision's approval every time
GBW07604 Folium Populi Pseudo-simonii makees Quality Control material.
(5) test data statistics: carry out variance analysis with SPSS software.
(6) result judges: model control group calcium content of bone or bone density are substantially less than sham operated rats, show
Cause the low drag of rat bone density；The calcium content of bone of ovary excision+animal subject group or bone density relatively model
Matched group dramatically increases, and is not less than the calcium carbonate control group of corresponding dosage, and other indexs (body weight is removed
It is not significantly lower than model control group outward), can determine that this tested material has the effect increasing bone density.Experiment
The results are shown in Table 2.
Table 2
Test result indicate that: calcium content of bone, femur center density, femur distal end density are significantly higher than mould
Type matched group P ＜ 0.05, this given the test agent (compositions described in embodiment 1-1) has that to dramatically increase bone close
The effect of degree.
Above-mentioned retouch in detail what the compositions for increasing bone density of the present invention was carried out with reference to embodiment
State, be illustrative rather than determinate, can according to restriction scope list several embodiments,
Therefore changing and modifications under without departing from present general inventive concept, within should belonging to protection scope of the present invention.
Claims (8)
1. the compositions being used for increasing bone density, it is characterised in that: by enzymolysis bone meal, collagen protein
Peptide, inulin, magnesium, first milk basic protein and yeast powder composition, enzymolysis bone meal 1-50 based on its parts by weight
Part, collagen peptide 1-20 part, inulin 1-50 part, magnesium 0.1-10 part, first milk basic protein 0.1-10
Part, yeast powder 0.01-10 part.
Compositions for increasing bone density the most according to claim 1, it is characterised in that: by it
Parts by weight meter enzymolysis bone meal 5-45 part, collagen peptide 2-15 part, inulin 3-40 part, magnesium 0.1-5
Part, first milk basic protein 0.1-5 part, yeast powder 0.01-5 part.
Compositions for increasing bone density the most according to claim 1, it is characterised in that: by it
Parts by weight meter enzymolysis bone meal 10-30 part, collagen peptide 2-10 part, inulin 5-30 part, magnesium 0.1-3
Part, first milk basic protein 0.1-3 part, yeast powder 0.01-4 part.
Compositions for increasing bone density the most according to claim 1, it is characterised in that: by it
Parts by weight meter enzymolysis bone meal 25 parts, collagen peptide 7 parts, inulin 18 parts, 2 parts of magnesium, colostrum alkali
2 parts of albumen of property, yeast powder 1.5 parts.
Compositions for increasing bone density the most according to claim 1, it is characterised in that: also wrap
Include the adjuvant of following parts by weight proportioning: cocoa powder 1-40 part, skimmed milk powder 1-40 part, seabuckthorn fruit powder
1-20 part, maltodextrin 1-40 part, fructose 0.1-30 part.
Compositions for increasing bone density the most according to claim 5, it is characterised in that: as follows
The adjuvant of parts by weight proportioning: cocoa powder 5-30 part, skimmed milk powder 5-30 part, seabuckthorn fruit powder 2-15 part,
Maltodextrin 2-20 part, fructose 0.1-20 part.
Compositions for increasing bone density the most according to claim 5, it is characterised in that: as follows
The adjuvant of parts by weight proportioning: cocoa powder 5-20 part, skimmed milk powder 5-30 part, seabuckthorn fruit powder 2-10 part,
Maltodextrin 5-20 part, fructose 1-15 part.
Compositions for increasing bone density the most according to claim 5, it is characterised in that: as follows
The adjuvant of parts by weight proportioning: cocoa powder 13 parts, skimmed milk powder 15 parts, seabuckthorn fruit powder 8 parts, Fructus Hordei Germinatus
6 parts of dextrin, fructose 5 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610428074.4A CN105996059A (en) | 2016-06-15 | 2016-06-15 | Composition for increasing bone mineral density |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610428074.4A CN105996059A (en) | 2016-06-15 | 2016-06-15 | Composition for increasing bone mineral density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105996059A true CN105996059A (en) | 2016-10-12 |
Family
ID=57088461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610428074.4A Withdrawn CN105996059A (en) | 2016-06-15 | 2016-06-15 | Composition for increasing bone mineral density |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105996059A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108576816A (en) * | 2018-03-09 | 2018-09-28 | 黑龙江飞鹤乳业有限公司 | A kind of composition increasing bone density |
| CN109198647A (en) * | 2017-07-03 | 2019-01-15 | 许昌神飞航天生物科技有限公司 | A kind of nutritional preparation that can improve spacefarer's bony structures |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211228A (en) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | Composition for increasing bone mineral density |
| CN105533712A (en) * | 2015-12-29 | 2016-05-04 | 天津天狮生物发展有限公司 | Composition used for increasing bone density and enhancing immunity |
-
2016
- 2016-06-15 CN CN201610428074.4A patent/CN105996059A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103211228A (en) * | 2013-04-11 | 2013-07-24 | 天津天狮生物发展有限公司 | Composition for increasing bone mineral density |
| CN105533712A (en) * | 2015-12-29 | 2016-05-04 | 天津天狮生物发展有限公司 | Composition used for increasing bone density and enhancing immunity |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109198647A (en) * | 2017-07-03 | 2019-01-15 | 许昌神飞航天生物科技有限公司 | A kind of nutritional preparation that can improve spacefarer's bony structures |
| CN108576816A (en) * | 2018-03-09 | 2018-09-28 | 黑龙江飞鹤乳业有限公司 | A kind of composition increasing bone density |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1903220B (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| CN103083650B (en) | Composition with bone mineral density addition function, and preparation method as well as application of composition | |
| CN105056216A (en) | Calcium supplementing preparation/granule and preparation method thereof | |
| CN102948762B (en) | Composition for weight reduction and its preparation method and use | |
| CN101496576B (en) | Special diet and foodstuffs formula containing small peptide for patient with bone fracture | |
| CN102318835A (en) | Composition for reducing bone loss and preparation method thereof | |
| CN101317684A (en) | Solid beverage and preparation method there of | |
| CN101536787A (en) | Sugar-free high-calcium albumen powder for improving senile osteoporosis | |
| AU2010212456B2 (en) | Formulas comprising calcium, magnesium, zinc, and vitamin D3, for the prevention and amelioration of osteoporosis | |
| CN102349653A (en) | Bone-invigorating collagen calcium granules | |
| CN106213492A (en) | A kind of lifter motion function also increases health-oriented products and the preparation method of bone density | |
| CN105533712A (en) | Composition used for increasing bone density and enhancing immunity | |
| CN103520711A (en) | Formula composition and medicinal preparation with effects of increasing bone density and treating bone joint pain, preparation method of medicinal preparation and application of formula composition | |
| CN109276710A (en) | A kind of composition and its preparation method and application increasing bone density | |
| CN1669478A (en) | Preparation method of vinegar-egg powder, compound containing vinegar-egg powder and application thereof | |
| CN105079028A (en) | Health care product capable of improving bones and joints and preparation method of health care product | |
| CN105996059A (en) | Composition for increasing bone mineral density | |
| CN103784939A (en) | Composition for enhancing bone mineral density | |
| CN101401833B (en) | Composition for preventing and/or treating osteoporosis | |
| CN101279089B (en) | Donkey-hide gelatin calcium composition and preparing process thereof | |
| CN104939089B (en) | With alimentation composition for improving bone substance density improving function and preparation method and application | |
| CN104146260A (en) | Health-care food for improving bone density and preparation method thereof | |
| Lotinun et al. | The study of a physiological significance of prolactin in the regulation of calcium metabolism during pregnancy and lactation in rats | |
| CN111569052A (en) | Composition for increasing bone mineral density of climacteric women and health product and application thereof | |
| CN101032523B (en) | Royal jelly acid calcium and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20161012 |